Brief: Innovation Pharma Completes Interim Safety Data Review
05/04/2021 12:47
April 5 (Reuters) - Innovation Pharmaceuticals Inc
IPIX.PK :
* INNOVATION PHARMA COMPLETES INTERIM SAFETY DATA REVIEW—DMC
APPROVES INCREASED DOSING FREQUENCY IN PHASE 2 CLINICAL TRIAL OF
BRILACIDIN IN HOSPITALIZED COVID-19 PATIENTS
Source text for Eikon: ID:nGNX9NCMN7
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review